Blockchain Registration Transaction Record

US-China Biotech Race Narrows, China Could Overtake by 2030

US still leads China in biotech, but China could overtake by 2030, says SCSP report. Learn how industrial capacity and national leverage are shifting the balance.

This news matters because biotechnology leadership has profound implications for national security, economic prosperity, and global health. The United States' ability to maintain its edge in biotech is not just about scientific prestige—it directly affects the country's capacity to respond to future pandemics, develop life-saving treatments, and compete in a strategic sector that China is aggressively targeting. The SCSP report underscores that without a more coordinated national strategy to support commercialization and manufacturing, the U.S. risks losing its competitive advantage to a rival that has systematically invested in industrial capacity and national leverage. As AI accelerates drug discovery, the race will increasingly hinge on speed to market and manufacturing scale—areas where China is already making significant strides. For policymakers, industry leaders, and the public, this report serves as a wake-up call to bolster America's biotech ecosystem and ensure that the nation remains at the forefront of innovation and security.